top of page
iPSC
Organoid Core
Partnered With
Patient-derived IPSCs and IPSC-generated organoids are first used to model the disease pathophysiology. This provides the closest in vitro model system to humans to delineate/uncover the underlying pathways that contribute to neurodegenerative diseases and further evaluate the efficacy of the therapeutics. Neurotherapeutics that pass this stage of validation are regarded as suitable for higher animal model testing.
MEET THE TEAM
DR. THOMAS DURCAN
TRIDENT Co-Principal Investigator and iPSC/Organoid Team Lead
Associate Professor, Department of Neurology and Neurosurgery,
McGill University
Director, The Neuro's Early Drug Discovery Unit (EDDU), McGill University
Email:
​​​
DR. EDWARD FON
TRIDENT Co-Principal Investigator and
iPSC/Organoid Team Lead
Professor, Department of Neurology
and Neurosurgery, McGill University
Scientific Director, The Neuro
(Montreal Neurological Institute-Hospital),
McGill University
Email:
​​​
Projects
Highly Qualified Personnel
Emmanuelle Nguyen Renou
Research Associate
McGill University
bottom of page